Loading
The Ministry of Health commission that decides whether Brazil's free public health system will pay for a new medicine, test or procedure, within a legal deadline of 180 days that can be extended by 90.
CONITEC advises Brazil's Ministry of Health on adding, removing or changing the health technologies the Sistema Único de Saúde (SUS) provides, and on the clinical protocols and therapeutic guidelines (PCDT) that govern their use. Its own page describes the legal framework as fixing a deadline of 180 days, extendable by a further 90, for a decision, and requires the analysis to rest on scientific evidence of efficacy, accuracy, effectiveness and safety and on a comparative economic evaluation against technologies the system already provides. A product must be registered with ANVISA before it can be assessed, and a medicine must also have its price regulated by the drug-pricing chamber CMED.
The commission works through three committees (medicines; products and procedures; clinical protocols), each with 17 voting member institutions, with the National Council of Justice, the National Council of the Public Prosecutor's Office and the public defenders' council taking part without a vote. Any person or organisation, including a patient, can ask for a technology to be assessed. Public consultations come with a plain-language report for society, and patients can give testimony on the condition and the technology (Perspectiva de Paciente).
A CONITEC recommendation is not the end of the road for a patient. The Ministry of Health announced in May 2026 that 23 high-cost cancer medicines, already incorporated, had waited up to 12 years to reach patients until a new funding table provided for them. For private health plans, the regulator ANS adds technologies that the SUS has incorporated on CONITEC's recommendation to its own coverage list within 60 days of the incorporation order. When a court is asked to order a medicine that is not on the SUS lists, CONITEC's page sets out the Supreme Federal Court's conditions, among them that CONITEC's refusal was unlawful or that no request was made or its analysis was excessively delayed.
Shares Prices and value, Most of the world has almost no cancer care.
Shares Agência Nacional de Vigilância Sanitária, Most of the world has almost no cancer care.
Shares Real-world evidence, Prices and value.
Shares Prices and value, Most of the world has almost no cancer care.
Shares Prices and value, Most of the world has almost no cancer care.
Shares Prices and value, Most of the world has almost no cancer care.
Shares Prices and value, Most of the world has almost no cancer care.
Shares Prices and value, Most of the world has almost no cancer care.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/